| 1 | Bladder cancer | Enrichment | BRCA1, CDKN1A, EGFR, FGFR3, HRAS, KRAS, PIK3CA, PTEN, TP53, TSC1 | 8.95 |
| 2 | Hemimegalencephaly | Enrichment | AKT3, MTOR, PIK3CA, PTEN, RHEB | 8.28 |
| 3 | Noonan syndrome and noonan-related syndrome | Enrichment | HRAS, KRAS, MAP2K1, MAP2K2, NRAS, RAF1, SOS1 | 7.85 |
| 4 | Lung non-small cell carcinoma | Enrichment | EGFR, HRAS, KRAS, MAP2K1, NRAS, PIK3CA | 7.31 |
| 5 | Noonan syndrome 1 | Enrichment | HRAS, KRAS, MAP2K1, MAP2K2, NRAS, RAF1, SOS1, SOS2 | 7.31 |
| 6 | Ehlers-danlos syndrome | Enrichment | COL1A1, COL1A2, COL3A1, COL5A1, COL5A2, THBS2, TNXB | 6.99 |
| 7 | Nevus, epidermal | Enrichment | FGFR3, HRAS, KRAS, NRAS, PIK3CA | 6.97 |
| 8 | Rasopathy | Enrichment | HRAS, KRAS, MAP2K1, MAP2K2, NRAS, RAF1, SOS1, SOS2 | 6.83 |
| 9 | Lip and oral cavity carcinoma | Enrichment | EGFR, HRAS, KIT, PIK3CA, STK11, TP53 | 6.72 |
| 10 | Colorectal cancer | Enrichment | AKT1, BRCA1, CCND1, FGFR2, FGFR3, IGF2, MET, NRAS, PIK3CA, PIK3R1, SGK2, TLR2, TP53 | 6.64 |
| 11 | Focal cortical dysplasia, type ii | Enrichment | MTOR, RHEB, TSC1, TSC2 | 6.62 |
| 12 | Isolated focal cortical dysplasia type ii | Enrichment | MTOR, RHEB, TSC1, TSC2 | 6.62 |
| 13 | Junctional epidermolysis bullosa | Enrichment | ITGA6, ITGB4, LAMA3, LAMB3, LAMC2 | 6.21 |
| 14 | Adult hepatocellular carcinoma | Enrichment | EGF, PIK3CA, TP53, TSC1, TSC2 | 5.96 |
| 15 | Ovarian cancer | Enrichment | AKT1, BRCA1, CDKN1B, EGFR, KIT, KRAS, MET, NTRK1, PDGFRA, PIK3CA, PTEN, TP53, TSC2 | 5.88 |
| 16 | Ehlers-danlos syndrome, classic type, 1 | Enrichment | COL1A1, COL1A2, COL5A1, COL5A2 | 5.46 |
| 17 | Epidermolysis bullosa, junctional 1a, intermediate | Enrichment | ITGB4, LAMA3, LAMB3, LAMC2 | 5.46 |
| 18 | Testicular germ cell tumor | Enrichment | FGFR3, KIT, KITLG, STK11 | 5.46 |
| 19 | Junctional epidermolysis bullosa non-herlitz type | Enrichment | ITGB4, LAMA3, LAMB3, LAMC2 | 5.46 |
| 20 | Keratoconus | Enrichment | COL1A1, COL4A1, COL5A2, TSC1 | 5.46 |
| 21 | Lung squamous cell carcinoma | Enrichment | EGFR, FGFR3, KRAS, PIK3CA | 5.46 |
| 22 | Classic ehlers-danlos syndrome | Enrichment | COL1A1, COL1A2, COL5A1, COL5A2 | 5.46 |
| 23 | Breast adenocarcinoma | Enrichment | AKT1, KRAS, PIK3CA, TP53 | 5.26 |
| 24 | Noonan syndrome 3 | Enrichment | HRAS, KRAS, RAF1, SOS1 | 5.10 |
| 25 | Gastric cancer | Enrichment | BRCA1, CDK4, FGFR2, KRAS, PIK3CA, PTEN, STK11, TP53 | 5.02 |
| 26 | Lacrimoauriculodentodigital syndrome 1 | Enrichment | FGF10, FGFR2, FGFR3 | 4.96 |
| 27 | Hamartoma | Enrichment | FGFR3, TSC1, TSC2 | 4.96 |
| 28 | Testicular germ cell cancer | Enrichment | FGFR3, KIT, STK11 | 4.96 |
| 29 | Lung cancer | Enrichment | BRCA1, EGFR, FASLG, KRAS, MET, PIK3CA, PPP2R1B | 4.95 |
| 30 | Pilomyxoid astrocytoma | Enrichment | FGFR1, KRAS, NTRK2, RAF1 | 4.90 |
| 31 | Multiple epiphyseal dysplasia due to collagen 9 anomaly | Enrichment | COL9A1, COL9A2, COL9A3 | 4.81 |
| 32 | Collagen vi-related dystrophies | Enrichment | COL6A1, COL6A2, COL6A3 | 4.81 |
| 33 | Intermediate collagen vi-related muscular dystrophy | Enrichment | COL6A1, COL6A2, COL6A3 | 4.81 |
| 34 | Digenic alport syndrome | Enrichment | COL4A3, COL4A4, COL4A5 | 4.81 |
| 35 | Kidney disease | Enrichment | COL4A3, COL4A4, COL4A5, LAMB2, TSC1 | 4.64 |
| 36 | Arteriovenous malformation | Enrichment | HRAS, MAP2K1, PIK3CA, TEK | 4.56 |
| 37 | Schimmelpenning-feuerstein-mims syndrome | Enrichment | HRAS, KRAS, NRAS | 4.37 |
| 38 | Cardiofaciocutaneous syndrome 1 | Enrichment | KRAS, MAP2K1, MAP2K2 | 4.37 |
| 39 | Megalencephaly-capillary malformation-polymicrogyria syndrome | Enrichment | AKT3, PIK3CA, PIK3R2 | 4.37 |
| 40 | Cardiofaciocutaneous syndrome | Enrichment | KRAS, MAP2K1, MAP2K2 | 4.37 |
| 41 | Myopathy, x-linked, with excessive autophagy | Enrichment | HRAS, MAP2K1, PIK3CA, TEK | 4.34 |
| 42 | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1 | Enrichment | AKT3, CCND2, PIK3R2 | 4.22 |
| 43 | Autosomal recessive stickler syndrome | Enrichment | COL9A1, COL9A2, COL9A3 | 4.22 |
| 44 | Bethlem muscular dystrophy | Enrichment | COL6A1, COL6A2, COL6A3 | 4.22 |
| 45 | Myeloma, multiple | Enrichment | CCND1, FGFR3, FLT3, IL7R, KRAS, PIK3R2, SGK1, TP53 | 4.16 |
| 46 | Stickler syndrome | Enrichment | COL2A1, COL9A1, COL9A2, COL9A3 | 4.15 |
| 47 | Nephrotic syndrome | Enrichment | COL4A3, COL4A4, COL4A5, FN1, ITGA3, LAMA5, LAMB2 | 4.07 |
| 48 | Breast cancer | Enrichment | AKT1, BRCA1, GNG3, IL2, IL7R, KRAS, PIK3CA, PTEN, TP53 | 4.00 |
| 49 | Meningioma | Enrichment | AKT1, PDGFB, PIK3CA, PTEN | 3.98 |
| 50 | Primary hypereosinophilic syndrome | Enrichment | FGFR1, PDGFRA, PDGFRB | 3.98 |
| 51 | Inherited cancer-predisposing syndrome | Enrichment | BRCA1, CDK4, CDKN1B, EGFR, KIT, MET, PDGFRA, PTEN, STK11, TP53, TSC1, TSC2 | 3.93 |
| 52 | Alport syndrome 3a, autosomal dominant | Enrichment | COL4A3, COL4A4, COL4A5 | 3.83 |
| 53 | Ullrich congenital muscular dystrophy 1a | Enrichment | COL6A1, COL6A2, COL6A3 | 3.83 |
| 54 | Autosomal dominant alport syndrome | Enrichment | COL4A3, COL4A4, COL4A5 | 3.83 |
| 55 | Alport syndrome | Enrichment | COL4A3, COL4A4, COL4A5 | 3.83 |
| 56 | Multisystem inflammatory syndrome in children | Enrichment | IFNA21, IFNA4, IFNA6, IFNAR2, IFNB1 | 3.76 |
| 57 | Cowden syndrome 1 | Enrichment | EGFR, PIK3CA, PTEN | 3.68 |
| 58 | Epidermolysis bullosa, junctional 1b, severe | Enrichment | LAMA3, LAMB3, LAMC2 | 3.68 |
| 59 | Fetomaternal alloimmune thrombocytopenia 1 | Enrichment | ITGA2, ITGA2B, ITGB3 | 3.68 |
| 60 | Type 2 diabetes mellitus | Enrichment | AKT2, INSR, IRS1, IRS2, SLC2A2, SLC2A4 | 3.51 |
| 61 | Lung cancer susceptibility 3 | Enrichment | EGFR, FGF10, KRAS, TP53 | 3.50 |
| 62 | Thyroid cancer, nonmedullary, 2 | Enrichment | HRAS, NRAS, PTEN | 3.45 |
| 63 | Capillary malformation-arteriovenous malformation 1 | Enrichment | KRAS, MAP2K1, PIK3CA | 3.45 |
| 64 | Follicular thyroid carcinoma | Enrichment | HRAS, NRAS, PTEN | 3.45 |
| 65 | Leukemia, acute myeloid | Enrichment | FLT3, JAK2, KIT, KRAS, NRAS, TP53 | 3.36 |
| 66 | Epiphyseal dysplasia, multiple, 1 | Enrichment | COL1A1, COMP | 3.31 |
| 67 | Ehlers-danlos syndrome, hypermobility type | Enrichment | COL3A1, TNXB | 3.31 |
| 68 | Spondyloepimetaphyseal dysplasia, strudwick type | Enrichment | COL2A1, FN1 | 3.31 |
| 69 | Spondylometaphyseal dysplasia, corner fracture type | Enrichment | COL2A1, FN1 | 3.31 |
| 70 | Otospondylomegaepiphyseal dysplasia, autosomal recessive | Enrichment | COL11A2, COL2A1 | 3.31 |
| 71 | Dermatofibrosarcoma protuberans | Enrichment | COL1A1, PDGFB | 3.31 |
| 72 | Lymphangioleiomyomatosis | Enrichment | TSC1, TSC2 | 3.31 |
| 73 | Keratosis, seborrheic | Enrichment | FGFR3, PIK3CA | 3.31 |
| 74 | Pfeiffer syndrome | Enrichment | FGFR1, FGFR2 | 3.31 |
| 75 | Jackson-weiss syndrome | Enrichment | FGFR1, FGFR2 | 3.31 |
| 76 | Encephalocraniocutaneous lipomatosis | Enrichment | FGFR1, KRAS | 3.31 |
| 77 | Ras-associated autoimmune leukoproliferative disorder | Enrichment | KRAS, NRAS | 3.31 |
| 78 | Otospondylomegaepiphyseal dysplasia, autosomal dominant | Enrichment | COL11A2, COL2A1 | 3.31 |
| 79 | Ehlers-danlos syndrome, arthrochalasia type, 2 | Enrichment | COL1A1, COL1A2 | 3.31 |
| 80 | Fibrochondrogenesis | Enrichment | COL11A1, COL11A2 | 3.31 |
| 81 | Rosette-forming glioneuronal tumor | Enrichment | FGFR1, PIK3CA | 3.31 |
| 82 | Stickler syndrome, type ii | Enrichment | COL11A1, COL1A1 | 3.31 |
| 83 | Ehlers-danlos/osteogenesis imperfecta syndrome | Enrichment | COL1A1, COL1A2 | 3.31 |
| 84 | Bethlem myopathy 1a | Enrichment | COL6A1, COL6A2, COL6A3 | 3.30 |
| 85 | Squamous cell carcinoma, head and neck | Enrichment | EGFR, PTEN, TP53 | 3.30 |
| 86 | Intervertebral disc disease | Enrichment | COL9A2, COL9A3, THBS2 | 3.30 |
| 87 | Gallbladder cancer | Enrichment | KRAS, PIK3CA, TP53 | 3.30 |
| 88 | Rhabdomyosarcoma | Enrichment | BRCA1, HRAS, PTEN, TP53 | 3.26 |
| 89 | Gliosarcoma | Enrichment | EGFR, FGFR1, FGFR3, TP53 | 3.26 |
| 90 | Melanocytic nevus syndrome, congenital | Enrichment | HRAS, NRAS, RAF1 | 3.25 |
| 91 | Cervical cancer | Enrichment | FGFR3, TP53 | 3.21 |
| 92 | Cervix carcinoma | Enrichment | FGFR3, TP53 | 3.21 |
| 93 | Arthritis | Enrichment | RELN, SYK | 3.21 |
| 94 | X-linked diffuse leiomyomatosis-alport syndrome | Enrichment | COL4A5, COL4A6 | 3.21 |
| 95 | Differentiated thyroid carcinoma | Enrichment | HRAS, KRAS, LPAR4, NRAS, NTRK1 | 3.16 |
| 96 | Giant cell glioblastoma | Enrichment | EGFR, FGFR1, FGFR3, TP53 | 3.15 |
| 97 | Hereditary breast carcinoma | Enrichment | AKT1, BRCA1, KRAS, PIK3CA, PTEN, TP53 | 3.13 |
| 98 | Cowden syndrome | Enrichment | AKT1, PIK3CA, PTEN | 3.08 |
| 99 | Primary bone dysplasia | Enrichment | COL1A1, COL1A2, FGFR3 | 2.93 |
| 100 | Crouzon syndrome | Enrichment | FGFR2, FGFR3 | 2.84 |
| 101 | Bleeding disorder, platelet-type, 16 | Enrichment | ITGA2B, ITGB3 | 2.84 |
| 102 | Telecanthus | Enrichment | COL11A1, COL5A2 | 2.84 |
| 103 | Tuberous sclerosis 1 | Enrichment | TSC1, TSC2 | 2.84 |
| 104 | Langerhans cell histiocytosis | Enrichment | MAP2K1, NRAS | 2.84 |
| 105 | Ehlers-danlos syndrome, classic type, 2 | Enrichment | COL5A1, COL5A2 | 2.84 |
| 106 | Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi | Enrichment | PIK3CA, PIK3R1 | 2.84 |
| 107 | Immunodeficiency 14a with lymphoproliferation, autosomal dominant | Enrichment | PIK3CD, PIK3R1 | 2.84 |
| 108 | Large congenital melanocytic nevus | Enrichment | HRAS, NRAS | 2.84 |
| 109 | Breast implant-associated anaplastic large cell lymphoma | Enrichment | JAK1, JAK2 | 2.84 |
| 110 | Immunodeficiency 14 | Enrichment | PIK3CD, PIK3R1 | 2.84 |
| 111 | Spermatocytoma | Enrichment | FGFR3, HRAS | 2.84 |
| 112 | High bone mass osteogenesis imperfecta | Enrichment | COL1A1, COL1A2 | 2.84 |
| 113 | Myxofibrosarcoma | Enrichment | CREB3L1, CREB3L2 | 2.84 |
| 114 | Multiple epiphyseal dysplasia | Enrichment | COL2A1, COMP | 2.84 |
| 115 | Testicular cancer | Enrichment | FGFR3, STK11 | 2.84 |
| 116 | Osteochondrodysplasia | Enrichment | COL1A1, COL1A2, FGFR3 | 2.80 |
| 117 | Endometrial cancer | Enrichment | BRCA1, FGFR2, PIK3CA, PTEN | 2.79 |
| 118 | Hematuria, benign familial, 1 | Enrichment | COL4A3, COL4A4 | 2.74 |
| 119 | High-grade b-cell lymphoma double-hit/triple-hit | Enrichment | BCL2, MYC | 2.74 |
| 120 | Dedifferentiated liposarcoma | Enrichment | CDK4, MDM2 | 2.74 |
| 121 | Phosphoenolpyruvate carboxykinase deficiency | Enrichment | PCK1, PCK2 | 2.74 |
| 122 | Well-differentiated liposarcoma | Enrichment | CDK4, MDM2 | 2.74 |
| 123 | Glycogen storage disease | Enrichment | G6PC1, GYS1, GYS2 | 2.66 |
| 124 | Precursor t-cell acute lymphoblastic leukemia | Enrichment | FLT3, MYB, MYC, TCL1A | 2.63 |
| 125 | Nk-cell enteropathy | Enrichment | IGF1R, JAK3, PIK3CB | 2.58 |
| 126 | Ehlers-danlos syndrome, arthrochalasia type, 1 | Enrichment | COL1A1, COL1A2 | 2.54 |
| 127 | Brain small vessel disease 1 with or without ocular anomalies | Enrichment | COL4A1, COL4A2 | 2.54 |
| 128 | Erythrocytosis, familial, 1 | Enrichment | EPOR, JAK2 | 2.54 |
| 129 | Saethre-chotzen syndrome | Enrichment | FGFR2, FGFR3 | 2.54 |
| 130 | Chronic myelogenous leukemia, bcr-abl1 positive | Enrichment | KRAS, NRAS | 2.54 |
| 131 | Tuberous sclerosis | Enrichment | TSC1, TSC2 | 2.54 |
| 132 | Osteogenesis imperfecta with normal sclerae, dominant form | Enrichment | COL1A1, COL1A2 | 2.54 |
| 133 | Glioma | Enrichment | FGFR2, PTEN | 2.54 |
| 134 | Pancreatic cancer | Enrichment | BRCA1, KRAS, STK11, TP53 | 2.49 |
| 135 | Multiple sclerosis | Enrichment | ITGB4, LAMA5, LAMB1 | 2.48 |
| 136 | Primary ovarian insufficiency | Enrichment | JAK2, KDR, NOS3, NTRK1, PRLR, THBS1 | 2.46 |
| 137 | Alport syndrome 2, autosomal recessive | Enrichment | COL4A3, COL4A4 | 2.44 |
| 138 | Lung sarcomatoid carcinoma | Enrichment | KRAS, TP53 | 2.44 |
| 139 | Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) | Enrichment | FLT3, KIT | 2.44 |
| 140 | Autosomal recessive alport syndrome | Enrichment | COL4A3, COL4A4 | 2.44 |
| 141 | Osteogenesis imperfecta, type iii | Enrichment | COL1A1, COL1A2, CREB3L1 | 2.39 |
| 142 | Myopia | Enrichment | COL11A1, COL2A1, COL4A4 | 2.39 |
| 143 | Non-immune hydrops fetalis | Enrichment | ANGPT2, FLT4, HRAS, KRAS | 2.33 |
| 144 | Hemifacial hyperplasia | Enrichment | FGFR2, FGFR3 | 2.33 |
| 145 | Insulin-like growth factor i | Enrichment | IGF1, IGF1R | 2.33 |
| 146 | Pre-eclampsia | Enrichment | FLT1, NOS3 | 2.33 |
| 147 | Holoprosencephaly | Enrichment | FGF8, FGFR1 | 2.33 |
| 148 | Epidermolysis bullosa | Enrichment | ITGA6, LAMB3 | 2.33 |
| 149 | Familial porencephaly | Enrichment | COL4A1, COL4A2 | 2.33 |
| 150 | Connective tissue disease | Enrichment | COL11A1, COL2A1, COL5A1, FGFR3 | 2.28 |
| 151 | Prostate cancer | Enrichment | BRCA1, PIK3CA, PTEN, TP53 | 2.26 |
| 152 | Retinal detachment | Enrichment | COL2A1, COL9A3 | 2.23 |
| 153 | Acute myeloid leukemia with maturation | Enrichment | FLT3, KIT | 2.23 |
| 154 | Acute megakaryocytic leukemia | Enrichment | PTEN, TP53 | 2.23 |
| 155 | Acute myeloid leukemia with t(8;21)(q22;q22) translocation | Enrichment | FLT3, KIT | 2.23 |
| 156 | Heart, malformation of | Enrichment | COL11A2, COL2A1, MAPK1 | 2.16 |
| 157 | Normosmic congenital hypogonadotropic hypogonadism | Enrichment | FGF17, FGF8, FGFR1 | 2.16 |
| 158 | Osteogenesis imperfecta, type i | Enrichment | COL1A1, COL1A2 | 2.16 |
| 159 | Holoprosencephaly 1 | Enrichment | FGF8, FGFR1 | 2.16 |
| 160 | Epidermolysis bullosa, junctional 5b, with pyloric atresia | Enrichment | ITGA6, ITGB4 | 2.16 |
| 161 | Hemangioma, capillary infantile | Enrichment | FLT4, KDR | 2.16 |
| 162 | Hemorrhage, intracerebral | Enrichment | COL4A1, COL4A2 | 2.16 |
| 163 | 46,xy disorder of sex development | Enrichment | FGFR3, INSR | 2.16 |
| 164 | Autosomal dominant secondary polycythemia | Enrichment | EPAS1, EPO | 2.16 |
| 165 | Li-fraumeni syndrome | Enrichment | MDM2, TP53 | 2.06 |
| 166 | Hemihyperplasia, isolated | Enrichment | IGF2, PIK3CA | 2.06 |
| 167 | Type 1 diabetes mellitus | Enrichment | IL6, INS | 2.06 |
| 168 | Multiple endocrine neoplasia, type i | Enrichment | CDKN1A, CDKN1B | 2.02 |
| 169 | Osteogenesis imperfecta, type ii | Enrichment | COL1A1, COL1A2 | 2.02 |
| 170 | Glanzmann thrombasthenia 1 | Enrichment | ITGA2B, ITGB3 | 2.02 |
| 171 | Gastrointestinal stromal tumor | Enrichment | KIT, PDGFRA | 2.02 |
| 172 | Leukemia, chronic myeloid | Enrichment | KRAS, NRAS | 2.02 |
| 173 | Renal cell carcinoma, papillary, 1 | Enrichment | MET, MTOR | 2.02 |
| 174 | Multiple enchondromatosis, maffucci type | Enrichment | COL2A1, HIF1A | 2.02 |
| 175 | Oligoarticular juvenile idiopathic arthritis | Enrichment | IL2RA, IL2RB | 2.02 |
| 176 | Overgrowth syndrome | Enrichment | MTOR, PIK3R1 | 2.02 |
| 177 | Rheumatoid factor-negative juvenile idiopathic arthritis | Enrichment | IL2RA, IL2RB | 2.02 |
| 178 | Cerebral palsy | Enrichment | COL4A1, COL4A2, GNB1, PDGFRB | 1.97 |
| 179 | Arteriovenous malformations of the brain | Enrichment | EGFR, IL6, KRAS | 1.95 |
| 180 | Neuropathy, hereditary sensory and autonomic, type v | Enrichment | NGF, NTRK1 | 1.92 |
| 181 | Essential thrombocythemia | Enrichment | JAK2, TP53 | 1.92 |
| 182 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) | Enrichment | FLT3, TP53 | 1.92 |
| 183 | Skin disease | Enrichment | ITGB4, LAMB3, LAMC2 | 1.91 |
| 184 | Basal ganglia calcification, idiopathic, 1 | Enrichment | PDGFB, PDGFRB | 1.90 |
| 185 | Brittle bone disorder | Enrichment | COL1A1, COL1A2, CREB3L1 | 1.86 |
| 186 | Kallmann syndrome | Enrichment | FGF17, FGF8, FGFR1 | 1.86 |
| 187 | Renal agenesis, bilateral | Enrichment | FGF20, ITGA8 | 1.79 |
| 188 | Familial thoracic aortic aneurysm and aortic dissection | Enrichment | COL1A1, COL3A1, COL5A1, COL5A2 | 1.79 |
| 189 | Hepatocellular carcinoma | Enrichment | MET, PIK3CA, TP53 | 1.78 |
| 190 | Amelogenesis imperfecta, type ie | Enrichment | ITGB6, LAMB3 | 1.70 |
| 191 | Omenn syndrome | Enrichment | IL2RG, IL7R | 1.70 |
| 192 | Melanoma | Enrichment | PTEN, STK11 | 1.70 |
| 193 | Autosomal dominant macrothrombocytopenia | Enrichment | ITGA2B, ITGB3 | 1.70 |
| 194 | Autosomal non-syndromic agammaglobulinemia | Enrichment | PIK3CD, PIK3R1 | 1.70 |
| 195 | Atypical chronic myeloid leukemia, bcr-abl1 negative | Enrichment | CSF3R, FLT3 | 1.70 |
| 196 | Amyloidosis, primary localized cutaneous, 1 | Enrichment | OSMR | 1.65 |
| 197 | Stickler syndrome, type i | Enrichment | COL2A1 | 1.65 |
| 198 | Hypochondroplasia | Enrichment | FGFR3 | 1.65 |
| 199 | Arthritis, sacroiliac | Enrichment | RELN | 1.65 |
| 200 | Macrodactyly | Enrichment | PIK3CA | 1.65 |
| 201 | Proteus syndrome | Enrichment | AKT1 | 1.65 |
| 202 | Beare-stevenson cutis gyrata syndrome | Enrichment | FGFR2 | 1.65 |
| 203 | Pyloric stenosis, infantile hypertrophic, 1 | Enrichment | NOS1 | 1.65 |
| 204 | Osteoglophonic dysplasia | Enrichment | FGFR1 | 1.65 |
| 205 | Epiphyseal dysplasia, multiple, with myopia and conductive deafness | Enrichment | COL2A1 | 1.65 |
| 206 | Thanatophoric dysplasia, type i | Enrichment | FGFR3 | 1.65 |
| 207 | Pseudoachondroplasia | Enrichment | COMP | 1.65 |
| 208 | Trigonocephaly 1 | Enrichment | FGFR1 | 1.65 |
| 209 | Hypoinsulinemic hypoglycemia with hemihypertrophy | Enrichment | AKT2 | 1.65 |
| 210 | Ehlers-danlos syndrome, cardiac valvular type | Enrichment | COL1A2 | 1.65 |
| 211 | Donohue syndrome | Enrichment | INSR | 1.65 |
| 212 | Spondylometaphyseal dysplasia, algerian type | Enrichment | COL2A1 | 1.65 |
| 213 | Von willebrand disease, type 1 | Enrichment | VWF | 1.65 |
| 214 | Spinocerebellar ataxia 27a | Enrichment | FGF14 | 1.65 |
| 215 | Hypothyroidism, congenital, nongoitrous, 9 | Enrichment | IRS4 | 1.65 |
| 216 | Oculoectodermal syndrome | Enrichment | KRAS | 1.65 |
| 217 | Muenke syndrome | Enrichment | FGFR3 | 1.65 |
| 218 | Vacterl association with hydrocephalus | Enrichment | PTEN | 1.65 |
| 219 | Premature aging syndrome, penttinen type | Enrichment | PDGFRB | 1.65 |
| 220 | Incontinentia pigmenti | Enrichment | IKBKG | 1.65 |
| 221 | Type 1 diabetes mellitus 10 | Enrichment | IL2RA | 1.65 |
| 222 | Deafness, autosomal recessive 53 | Enrichment | COL11A2 | 1.65 |
| 223 | Hyperinsulinemic hypoglycemia, familial, 5 | Enrichment | INSR | 1.65 |
| 224 | Osteoarthritis with mild chondrodysplasia | Enrichment | COL2A1 | 1.65 |
| 225 | Autoinflammatory disease, systemic, x-linked | Enrichment | IKBKG | 1.65 |
| 226 | Avascular necrosis of femoral head, primary, 1 | Enrichment | COL2A1 | 1.65 |
| 227 | Noonan syndrome 5 | Enrichment | RAF1 | 1.65 |
| 228 | Pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities | Enrichment | INSR | 1.65 |
| 229 | Hypomagnesemia 4, renal | Enrichment | EGF | 1.65 |
| 230 | Czech dysplasia | Enrichment | COL2A1 | 1.65 |
| 231 | Diabetes mellitus, insulin-resistant, with acanthosis nigricans | Enrichment | INSR | 1.65 |
| 232 | Noonan syndrome 4 | Enrichment | SOS1 | 1.65 |
| 233 | Hypereosinophilic syndrome, idiopathic | Enrichment | PDGFRA | 1.65 |
| 234 | Deafness, autosomal recessive 39 | Enrichment | HGF | 1.65 |
| 235 | Mastocytosis, cutaneous | Enrichment | KIT | 1.65 |
| 236 | Stomatin-deficient cryohydrocytosis with neurologic defects | Enrichment | SLC2A1 | 1.65 |
| 237 | Spinocerebellar ataxia 12 | Enrichment | PPP2R2B | 1.65 |
| 238 | Scaphocephaly, maxillary retrusion, and impaired intellectual development | Enrichment | FGFR2 | 1.65 |
| 239 | Marshall syndrome | Enrichment | COL11A1 | 1.65 |
| 240 | Melorheostosis, isolated | Enrichment | MAP2K1 | 1.65 |
| 241 | Megalencephaly, autosomal dominant | Enrichment | PIK3CA | 1.65 |
| 242 | Kniest dysplasia | Enrichment | COL2A1 | 1.65 |
| 243 | Apert syndrome | Enrichment | FGFR2 | 1.65 |
| 244 | Cardiomyopathy, dilated, 1jj | Enrichment | LAMA4 | 1.65 |
| 245 | Basal ganglia calcification, idiopathic, 5 | Enrichment | PDGFB | 1.65 |
| 246 | Hyperpigmentation with or without hypopigmentation, familial progressive | Enrichment | KITLG | 1.65 |
| 247 | Platyspondylic lethal skeletal dysplasia, torrance type | Enrichment | COL2A1 | 1.65 |
| 248 | Mucoepithelial dysplasia, hereditary | Enrichment | SREBF1 | 1.65 |
| 249 | Cardiomyopathy, dilated, 1nn | Enrichment | RAF1 | 1.65 |
| 250 | Cowden syndrome 5 | Enrichment | PIK3CA | 1.65 |
| 251 | Von willebrand disease, type 2 | Enrichment | VWF | 1.65 |
| 252 | Cardiofaciocutaneous syndrome 3 | Enrichment | MAP2K1 | 1.65 |
| 253 | Myofibromatosis, infantile, 1 | Enrichment | PDGFRB | 1.65 |
| 254 | Fibrochondrogenesis 1 | Enrichment | COL11A1 | 1.65 |
| 255 | Melanosis, neurocutaneous | Enrichment | NRAS | 1.65 |
| 256 | Multiple fibroadenomas of the breast | Enrichment | PRLR | 1.65 |
| 257 | Thanatophoric dysplasia, type ii | Enrichment | FGFR3 | 1.65 |
| 258 | Spondyloepiphyseal dysplasia, stanescu type | Enrichment | COL2A1 | 1.65 |
| 259 | Noonan syndrome 6 | Enrichment | NRAS | 1.65 |
| 260 | Lissencephaly 5 | Enrichment | LAMB1 | 1.65 |
| 261 | Osteogenesis imperfecta, type xvi | Enrichment | CREB3L1 | 1.65 |
| 262 | Hypogonadotropic hypogonadism 20 with or without anosmia | Enrichment | FGF17 | 1.65 |
| 263 | Deafness, autosomal dominant 56 | Enrichment | TNC | 1.65 |
| 264 | Gist-plus syndrome | Enrichment | PDGFRA | 1.65 |
| 265 | Microvascular complications of diabetes 2 | Enrichment | EPO | 1.65 |
| 266 | Camptodactyly, tall stature, and hearing loss syndrome | Enrichment | FGFR3 | 1.65 |
| 267 | Ataxia-oculomotor apraxia 3 | Enrichment | PIK3R5 | 1.65 |
| 268 | Accelerated tumor formation | Enrichment | MDM2 | 1.65 |
| 269 | Aplasia of lacrimal and salivary glands | Enrichment | FGF10 | 1.65 |
| 270 | Bent bone dysplasia syndrome 1 | Enrichment | FGFR2 | 1.65 |
| 271 | Acrogeria, gottron type | Enrichment | COL3A1 | 1.65 |
| 272 | Achondrogenesis, type ii | Enrichment | COL2A1 | 1.65 |
| 273 | Carpal tunnel syndrome 2 | Enrichment | COMP | 1.65 |
| 274 | Hypertriglyceridemia 2 | Enrichment | CREB3L3 | 1.65 |
| 275 | Angioedema, hereditary, 5 | Enrichment | ANGPT1 | 1.65 |
| 276 | Cerebral cavernous malformations 4 | Enrichment | PIK3CA | 1.65 |
| 277 | Immunodeficiency 15b | Enrichment | IKBKB | 1.65 |
| 278 | Neurodevelopmental disorder with hypotonia and dysmorphic facies | Enrichment | GNB2 | 1.65 |
| 279 | Neurodevelopmental disorder, nonprogressive, with spasticity and transient opisthotonus | Enrichment | TNR | 1.65 |
| 280 | Noonan syndrome 13 | Enrichment | MAPK1 | 1.65 |
| 281 | Immunodeficiency 106 viral infections | Enrichment | IFNAR1 | 1.65 |
| 282 | Nephrotic syndrome, type 26 | Enrichment | LAMA5 | 1.65 |
| 283 | Deafness, x-linked 6 | Enrichment | COL4A6 | 1.65 |
| 284 | Immunodeficiency 15a | Enrichment | IKBKB | 1.65 |
| 285 | Intellectual developmental disorder, x-linked 110 | Enrichment | FGF13 | 1.65 |
| 286 | Spinocerebellar ataxia 27b, late-onset | Enrichment | FGF14 | 1.65 |
| 287 | Venous malformations, multiple cutaneous and mucosal | Enrichment | TEK | 1.65 |
| 288 | Immunodeficiency 63 with lymphoproliferation and autoimmunity | Enrichment | IL2RB | 1.65 |
| 289 | Lessel-kubisch syndrome | Enrichment | MDM2 | 1.65 |
| 290 | Ullrich congenital muscular dystrophy 1b | Enrichment | COL6A2 | 1.65 |
| 291 | Short syndrome | Enrichment | PIK3R1 | 1.65 |
| 292 | Von willebrand disease, type 3 | Enrichment | VWF | 1.65 |
| 293 | Houge-janssens syndrome 4 | Enrichment | PPP2R5C | 1.65 |
| 294 | Fetomaternal alloimmune thrombocytopenia 2 | Enrichment | ITGA2B | 1.65 |
| 295 | Ectodermal dysplasia and immunodeficiency 1 | Enrichment | IKBKG | 1.65 |
| 296 | Combined osteogenesis imperfecta and ehlers-danlos syndrome 2 | Enrichment | COL1A2 | 1.65 |
| 297 | Hereditary lymphedema id | Enrichment | VEGFC | 1.65 |
| 298 | Acetyl-coa carboxylase-alpha deficiency | Enrichment | ACACA | 1.65 |
| 299 | Osteofibrous dysplasia | Enrichment | MET | 1.65 |
| 300 | Spondyloperipheral dysplasia | Enrichment | COL2A1 | 1.65 |
| 301 | Myosclerosis, autosomal recessive | Enrichment | COL6A2 | 1.65 |
| 302 | Laron syndrome | Enrichment | GHR | 1.65 |
| 303 | Porencephaly | Enrichment | COL4A1 | 1.65 |
| 304 | Oculoskeletodental syndrome | Enrichment | PIK3C2A | 1.65 |
| 305 | Deafness, autosomal dominant 37 | Enrichment | COL11A1 | 1.65 |
| 306 | Autism 19 | Enrichment | EIF4E | 1.65 |
| 307 | Myeloid and lymphoid neoplasms associated with pdgfra rearrangement | Enrichment | PDGFRA | 1.65 |
| 308 | Ifap syndrome 2 | Enrichment | SREBF1 | 1.65 |
| 309 | Developmental and epileptic encephalopathy 90 | Enrichment | FGF13 | 1.65 |
| 310 | Metacarpal 4-5 fusion | Enrichment | FGF16 | 1.65 |
| 311 | Hyperprolactinemia | Enrichment | PRLR | 1.65 |
| 312 | Lymphatic malformation 4 | Enrichment | VEGFC | 1.65 |
| 313 | Growth hormone insensitivity, partial | Enrichment | GHR | 1.65 |
| 314 | Papillary tumor of the pineal region | Enrichment | PTEN | 1.65 |
| 315 | Lacrimoauriculodentodigital syndrome 3 | Enrichment | FGF10 | 1.65 |
| 316 | Cardiofaciocutaneous syndrome 2 | Enrichment | KRAS | 1.65 |
| 317 | Houge-janssens syndrome 2 | Enrichment | PPP2R1A | 1.65 |
| 318 | Deafness, autosomal dominant 13 | Enrichment | COL11A2 | 1.65 |
| 319 | Deafness, autosomal recessive 97 | Enrichment | MET | 1.65 |
| 320 | Microvascular complications of diabetes 1 | Enrichment | VEGFA | 1.65 |
| 321 | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2 | Enrichment | AKT3 | 1.65 |
| 322 | Skin/hair/eye pigmentation, variation in, 7 | Enrichment | KITLG | 1.65 |
| 323 | Crouzon syndrome with acanthosis nigricans | Enrichment | FGFR3 | 1.65 |
| 324 | Hemifacial myohyperplasia | Enrichment | PIK3CA | 1.65 |
| 325 | Neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | Enrichment | RAB11B | 1.65 |
| 326 | Capillary malformation of the lower lip, lymphatic malformation of face and neck, asymmetry of face and limbs, and partial/generalized overgrowth | Enrichment | PIK3CA | 1.65 |
| 327 | Melorheostosis | Enrichment | MAP2K1 | 1.65 |
| 328 | Neuroendocrine tumor | Enrichment | CDKN1B | 1.65 |
| 329 | Autism 9 | Enrichment | MET | 1.65 |
| 330 | Stickler syndrome, type i, nonsyndromic ocular | Enrichment | COL2A1 | 1.65 |
| 331 | Leopard syndrome 2 | Enrichment | RAF1 | 1.65 |
| 332 | Erythrocytosis, familial, 4 | Enrichment | EPAS1 | 1.65 |
| 333 | Multiple synostoses syndrome 3 | Enrichment | FGF9 | 1.65 |
| 334 | Interleukin 6, serum level of, quantitative trait locus | Enrichment | IL6R | 1.65 |
| 335 | Cortical malformations, occipital | Enrichment | LAMC3 | 1.65 |
| 336 | Epilepsy, idiopathic generalized 12 | Enrichment | SLC2A1 | 1.65 |
| 337 | Basal ganglia calcification, idiopathic, 4 | Enrichment | PDGFRB | 1.65 |
| 338 | Soluble interleukin-6 receptor, serum level of, quantitative trait locus | Enrichment | IL6R | 1.65 |
| 339 | Immunodeficiency 36 with lymphoproliferation | Enrichment | PIK3R1 | 1.65 |
| 340 | Cardiofaciocutaneous syndrome 4 | Enrichment | MAP2K2 | 1.65 |
| 341 | Cowden syndrome 6 | Enrichment | AKT1 | 1.65 |
| 342 | Hyper-ige syndrome 5, autosomal recessive, with recurrent infections | Enrichment | IL6R | 1.65 |
| 343 | Fibrochondrogenesis 2 | Enrichment | COL11A2 | 1.65 |
| 344 | Synovitis | Enrichment | RELN | 1.65 |
| 345 | Immunodeficiency 14b, autosomal recessive | Enrichment | PIK3CD | 1.65 |
| 346 | Myeloid and lymphoid neoplasms associated with pdgfrb rearrangement | Enrichment | PDGFRB | 1.65 |
| 347 | Charcot-marie-tooth disease, dominant intermediate f | Enrichment | GNB4 | 1.65 |
| 348 | Agammaglobulinemia 7, autosomal recessive | Enrichment | PIK3R1 | 1.65 |
| 349 | Immunodeficiency 97 with autoinflammation | Enrichment | PIK3CG | 1.65 |
| 350 | Hypogonadotropic hypogonadism 6 with or without anosmia | Enrichment | FGF8 | 1.65 |
| 351 | Glioma susceptibility 2 | Enrichment | PTEN | 1.65 |
| 352 | Achondroplasia, severe, with developmental delay and acanthosis nigricans | Enrichment | FGFR3 | 1.65 |
| 353 | Kosaki overgrowth syndrome | Enrichment | PDGFRB | 1.65 |
| 354 | Erythrocytosis, familial, 5 | Enrichment | EPO | 1.65 |
| 355 | Hartsfield syndrome | Enrichment | FGFR1 | 1.65 |
| 356 | Congenital heart defects, multiple types, 7 | Enrichment | FLT4 | 1.65 |
| 357 | Renal hypodysplasia/aplasia 2 | Enrichment | FGF20 | 1.65 |
| 358 | Intellectual developmental disorder, autosomal dominant 42 | Enrichment | GNB1 | 1.65 |
| 359 | Glaucoma 3, primary congenital, e | Enrichment | TEK | 1.65 |
| 360 | Sick sinus syndrome 4 | Enrichment | GNB2 | 1.65 |
| 361 | Von willebrand's disease | Enrichment | VWF | 1.65 |
| 362 | Qualitative or quantitative defects of collagen 6 | Enrichment | COL6A2 | 1.65 |
| 363 | Brain abnormalities, neurodegeneration, and dysosteosclerosis | Enrichment | CSF1R | 1.65 |
| 364 | Developmental and epileptic encephalopathy 47 | Enrichment | FGF12 | 1.65 |
| 365 | Ocular pterygium-digital keloid dysplasia syndrome | Enrichment | PDGFRB | 1.65 |
| 366 | Chronic mast cell leukemia | Enrichment | KIT | 1.65 |
| 367 | Trigonitis | Enrichment | RAF1 | 1.65 |
| 368 | Bent bone dysplasia syndrome 2 | Enrichment | LAMA5 | 1.65 |
| 369 | Vitreoretinopathy with phalangeal epiphyseal dysplasia | Enrichment | COL2A1 | 1.65 |
| 370 | Segmental progressive overgrowth syndrome with fibroadipose hyperplasia | Enrichment | PIK3CA | 1.65 |
| 371 | Tufted angioma of skin | Enrichment | KDR | 1.65 |
| 372 | Asphyxia neonatorum | Enrichment | COL1A1 | 1.65 |
| 373 | Deafness, autosomal dominant 69 | Enrichment | KITLG | 1.65 |
| 374 | Bethlem myopathy 1b | Enrichment | COL6A2 | 1.65 |
| 375 | T-b+ severe combined immunodeficiency due to jak3 deficiency | Enrichment | JAK3 | 1.65 |
| 376 | Arthrogryposis, distal, type 11 | Enrichment | MET | 1.65 |
| 377 | Amelogenesis imperfecta, type ih | Enrichment | ITGB6 | 1.65 |
| 378 | Lacrimoauriculodentodigital syndrome 2 | Enrichment | FGFR3 | 1.65 |
| 379 | Csf1r-related disorder | Enrichment | CSF1R | 1.65 |
| 380 | Col4a1-related disorders | Enrichment | COL4A1 | 1.65 |
| 381 | Occipital pachygyria and polymicrogyria | Enrichment | LAMC3 | 1.65 |
| 382 | Short-rib thoracic dysplasia 22 without polydactyly | Enrichment | FGF4 | 1.65 |
| 383 | Hypospadias | Enrichment | PIK3CA | 1.65 |
| 384 | Bockenheimer syndrome | Enrichment | TEK | 1.65 |
| 385 | Capillary hemangioma | Enrichment | AKT3 | 1.65 |
| 386 | Familial hyperprolactinemia | Enrichment | PRLR | 1.65 |
| 387 | Multiple paragangliomas associated with polycythemia | Enrichment | EPAS1 | 1.65 |
| 388 | Isolated bone marrow mastocytosis | Enrichment | KIT | 1.65 |
| 389 | Congenital pulmonary airway malformation | Enrichment | KRAS | 1.65 |
| 390 | Autosomal dominant rhegmatogenous retinal detachment | Enrichment | COL2A1 | 1.65 |
| 391 | Smoldering systemic mastocytosis | Enrichment | KIT | 1.65 |
| 392 | Rare venous malformation | Enrichment | PIK3CA | 1.65 |
| 393 | Fetomaternal alloimmune thrombocytopenia 3 | Enrichment | ITGA2 | 1.65 |
| 394 | Col4a1 or col4a2-related cerebral small vessel disease | Enrichment | COL4A1 | 1.65 |
| 395 | Multiple epiphyseal dysplasia with myopia and deafness | Enrichment | COL2A1 | 1.65 |
| 396 | Immune dysregulation, neurodevelopmental defects, and colitis | Enrichment | ITGAV | 1.65 |
| 397 | Spinocerebellar ataxia type 27b | Enrichment | FGF14 | 1.65 |
| 398 | Diaphragmatic eventration | Enrichment | PIK3CA | 1.65 |
| 399 | Hypochondrogenesis | Enrichment | COL2A1 | 1.65 |
| 400 | Fgfr3-related chondrodysplasia | Enrichment | FGFR3 | 1.65 |
| 401 | Chronic neutrophilic leukemia | Enrichment | CSF3R | 1.65 |
| 402 | Pneumothorax | Enrichment | COL5A1 | 1.65 |
| 403 | Mastocytosis | Enrichment | KIT | 1.65 |
| 404 | Pik3ca-related overgrowth spectrum | Enrichment | PIK3CA | 1.65 |
| 405 | Congenital primary lymphedema of gordon | Enrichment | VEGFC | 1.65 |
| 406 | Camptodactyly-tall stature-scoliosis-hearing loss syndrome | Enrichment | FGFR3 | 1.65 |
| 407 | Epilepsy with myoclonic absences | Enrichment | SLC2A1 | 1.65 |
| 408 | Autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome | Enrichment | COL11A1 | 1.65 |
| 409 | Familial progressive hyperpigmentation | Enrichment | KITLG | 1.65 |
| 410 | Dysspondyloenchondromatosis | Enrichment | COL2A1 | 1.65 |
| 411 | Early-onset calcifying leukoencephalopathy-skeletal dysplasia | Enrichment | CSF1R | 1.65 |
| 412 | Cystic lymphangioma | Enrichment | COL11A2 | 1.65 |
| 413 | Rare combined vascular malformation | Enrichment | PIK3CA | 1.65 |
| 414 | Abdominal aortic aneurysm | Enrichment | COL3A1 | 1.65 |
| 415 | Cavernous lymphangioma | Enrichment | PIK3CA | 1.65 |
| 416 | Pik3ca-related overgrowth syndrome | Enrichment | PIK3CA | 1.65 |
| 417 | Cutaneous mastocytoma | Enrichment | KIT | 1.65 |
| 418 | Oculocerebrodental syndrome | Enrichment | PIK3C2A | 1.65 |
| 419 | Typical urticaria pigmentosa | Enrichment | KIT | 1.65 |
| 420 | T-b+ severe combined immunodeficiency due to il-7ralpha deficiency | Enrichment | IL7R | 1.65 |
| 421 | Phakomatosis pigmentokeratotica | Enrichment | HRAS | 1.65 |
| 422 | Ppp2r1a-related neurodevelopmental disorder | Enrichment | PPP2R1A | 1.65 |
| 423 | Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome | Enrichment | PTEN | 1.65 |
| 424 | Nodular urticaria pigmentosa | Enrichment | KIT | 1.65 |
| 425 | Type 2 collagen-related bone disorder | Enrichment | COL2A1 | 1.65 |
| 426 | Intestinal polyposis syndrome | Enrichment | STK11 | 1.65 |
| 427 | Hartsfield-bixler-demyer syndrome | Enrichment | FGFR1 | 1.65 |
| 428 | Hemihyperplasia-multiple lipomatosis syndrome | Enrichment | PIK3CA | 1.65 |
| 429 | Pseudoxanthomatous diffuse cutaneous mastocytosis | Enrichment | KIT | 1.65 |
| 430 | Lama5-related multisystemic syndrome | Enrichment | LAMA5 | 1.65 |
| 431 | Telangiectasia macularis eruptiva perstans | Enrichment | KIT | 1.65 |
| 432 | Acute mast cell leukemia | Enrichment | KIT | 1.65 |
| 433 | Mendelian susceptibility to mycobacterial diseases due to partial jak1 deficiency | Enrichment | JAK1 | 1.65 |
| 434 | Eccrine angiomatous hamartoma | Enrichment | PIK3CA | 1.65 |
| 435 | Egf-related primary hypomagnesemia with intellectual disability | Enrichment | EGF | 1.65 |
| 436 | Non-syndromic unicoronal craniosynostosis | Enrichment | FGFR2 | 1.65 |
| 437 | Familial progressive hyper- and hypopigmentation | Enrichment | KITLG | 1.65 |
| 438 | Plaque-form urticaria pigmentosa | Enrichment | KIT | 1.65 |
| 439 | Interstitial lung disease specific to childhood | Enrichment | FGF10 | 1.65 |
| 440 | Macrodactyly of toe | Enrichment | PIK3CA | 1.65 |
| 441 | Neurocutaneous melanocytosis | Enrichment | NRAS | 1.65 |
| 442 | Hereditary cryohydrocytosis with reduced stomatin | Enrichment | SLC2A1 | 1.65 |
| 443 | Bullous diffuse cutaneous mastocytosis | Enrichment | KIT | 1.65 |
| 444 | Laminin subunit alpha 2-related muscular dystrophy | Enrichment | LAMA2 | 1.65 |
| 445 | Akt2-related familial partial lipodystrophy | Enrichment | AKT2 | 1.65 |
| 446 | Testis seminoma | Enrichment | KIT | 1.65 |
| 447 | Meningioma, familial | Enrichment | PDGFB, PTEN | 1.62 |
| 448 | Specific learning disability | Enrichment | GHR, MAPK1 | 1.62 |
| 449 | Leukemia, chronic lymphocytic | Enrichment | CCND1, TP53 | 1.61 |
| 450 | Palmoplantar keratoderma, punctate type ii | Enrichment | BRCA1 | 1.60 |
| 451 | Leprosy 3 | Enrichment | TLR2 | 1.60 |
| 452 | Phosphoenolpyruvate carboxykinase deficiency, cytosolic | Enrichment | PCK1 | 1.60 |
| 453 | Alport syndrome 1, x-linked | Enrichment | COL4A5 | 1.60 |
| 454 | Melanoma, cutaneous malignant 3 | Enrichment | CDK4 | 1.60 |
| 455 | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3 | Enrichment | CCND2 | 1.60 |
| 456 | Microcephaly 12, primary, autosomal recessive | Enrichment | CDK6 | 1.60 |
| 457 | Noonan syndrome 9 | Enrichment | SOS2 | 1.60 |
| 458 | Fetal encasement syndrome | Enrichment | CHUK | 1.60 |
| 459 | Epiphyseal dysplasia, multiple, 6 | Enrichment | COL9A1 | 1.60 |
| 460 | Immunodeficiency 82 with systemic inflammation | Enrichment | SYK | 1.60 |
| 461 | Developmental and epileptic encephalopathy 58 | Enrichment | NTRK2 | 1.60 |
| 462 | Brunet-wagner neurodevelopmental syndrome | Enrichment | RBL2 | 1.60 |
| 463 | Immunodeficiency 130 with hpv-related verrucosis | Enrichment | IL7 | 1.60 |
| 464 | Epiphyseal dysplasia, multiple, 2 | Enrichment | COL9A2 | 1.60 |
| 465 | Bone marrow failure syndrome 5 | Enrichment | TP53 | 1.60 |
| 466 | Papilloma of choroid plexus | Enrichment | TP53 | 1.60 |
| 467 | Basal cell carcinoma 7 | Enrichment | TP53 | 1.60 |
| 468 | Ullrich congenital muscular dystrophy 1c | Enrichment | COL6A3 | 1.60 |
| 469 | Anaplastic thyroid carcinoma | Enrichment | TP53 | 1.60 |
| 470 | Infant-type hemispheric glioma | Enrichment | BRCA1 | 1.60 |
| 471 | Epiphyseal dysplasia, multiple, 3 | Enrichment | COL9A3 | 1.60 |
| 472 | Familial isolated trichomegaly | Enrichment | FGF5 | 1.60 |
| 473 | Lodder-merla syndrome, type 2, with developmental delay and with or without cardiac arrhythmia | Enrichment | GNB5 | 1.60 |
| 474 | Stickler syndrome, type iv | Enrichment | COL9A1 | 1.60 |
| 475 | Glaucoma 1, open angle, o | Enrichment | NTF4 | 1.60 |
| 476 | Dystonia 27 | Enrichment | COL6A3 | 1.60 |
| 477 | Immunodeficiency, common variable, 3 | Enrichment | CD19 | 1.60 |
| 478 | Acute myeloid leukemia with minimal differentiation | Enrichment | FLT3 | 1.60 |
| 479 | Macular degeneration, age-related, 10 | Enrichment | TLR4 | 1.60 |
| 480 | Obesity, hyperphagia, and developmental delay | Enrichment | NTRK2 | 1.60 |
| 481 | Ductal carcinoma in situ | Enrichment | TP53 | 1.60 |
| 482 | Stickler syndrome, type v | Enrichment | COL9A2 | 1.60 |
| 483 | Tumoral calcinosis, hyperphosphatemic, familial, 2 | Enrichment | FGF23 | 1.60 |
| 484 | Bartsocas-papas syndrome 2 | Enrichment | CHUK | 1.60 |
| 485 | Thyroid gland undifferentiated carcinoma | Enrichment | TP53 | 1.60 |
| 486 | Small-cell carcinoma of the ovary of hypercalcemic type | Enrichment | TP53 | 1.60 |
| 487 | Immunodeficiency 125 | Enrichment | FLT3LG | 1.60 |
| 488 | Bethlem myopathy 1c | Enrichment | COL6A3 | 1.60 |
| 489 | Retinal lattice degeneration | Enrichment | COL9A3 | 1.60 |
| 490 | Diffuse pediatric-type high-grade glioma, h3-wildtype and idh-wildtype | Enrichment | TP53 | 1.60 |
| 491 | Colitis | Enrichment | SYK | 1.60 |
| 492 | Choroid plexus cancer | Enrichment | TP53 | 1.60 |
| 493 | X-linked alport syndrome | Enrichment | COL4A5 | 1.60 |
| 494 | Combined immunodeficiency-hypogammaglobulinemia-skeletal anomalies syndrome due to ikbka deficiency | Enrichment | CHUK | 1.60 |
| 495 | Pleomorphic xanthoastrocytoma | Enrichment | TP53 | 1.60 |
| 496 | Microcephaly-corpus callosum and cerebellar vermis hypoplasia-facial dysmorphism-intellectual disability syndrom | Enrichment | RAC1 | 1.60 |
| 497 | Primary peritoneal carcinoma | Enrichment | BRCA1 | 1.60 |
| 498 | Juvenile myelomonocytic leukemia | Enrichment | KRAS, NRAS | 1.55 |
| 499 | Hypertelorism | Enrichment | COL11A1, COL1A1, FGFR2, PIK3CA | 1.55 |
| 500 | Rare autosomal dominant non-syndromic sensorineural deafness type dfna | Enrichment | COL11A1, COL11A2, KITLG, TNC | 1.55 |
| 501 | Leukemia, acute lymphoblastic | Enrichment | FLT3, GNB1 | 1.53 |
| 502 | Myelodysplastic syndrome | Enrichment | GNB1, TP53 | 1.53 |
| 503 | Uterine corpus cancer | Enrichment | BRCA1, PTEN | 1.53 |
| 504 | Osteogenesis imperfecta, type iv | Enrichment | COL1A1, COL1A2 | 1.48 |
| 505 | Severe combined immunodeficiency | Enrichment | IKBKB, IL7R, JAK3 | 1.44 |
| 506 | Osteoporosis | Enrichment | COL1A1, COL1A2 | 1.42 |
| 507 | Cataract | Enrichment | COL5A1, EPHA2 | 1.42 |
| 508 | Chronic kidney disease | Enrichment | COL4A4, COL4A5 | 1.39 |
| 509 | Renal cell carcinoma, nonpapillary | Enrichment | MET, MTOR | 1.37 |
| 510 | Hydrocephalus | Enrichment | FGFR2, PDGFRB | 1.37 |
| 511 | Lynch syndrome | Enrichment | KRAS, PIK3CA | 1.37 |
| 512 | Ehlers-danlos syndrome, vascular type | Enrichment | COL3A1 | 1.36 |
| 513 | Lymphatic malformation 1 | Enrichment | FLT4 | 1.36 |
| 514 | Amelogenesis imperfecta, type ia | Enrichment | LAMB3 | 1.36 |
| 515 | Leukocyte adhesion deficiency, type i | Enrichment | ITGB2 | 1.36 |
| 516 | Peutz-jeghers syndrome | Enrichment | STK11 | 1.36 |
| 517 | Blue rubber bleb nevus | Enrichment | TEK | 1.36 |
| 518 | Myeloproliferative disorder, chronic, with eosinophilia | Enrichment | PDGFRB | 1.36 |
| 519 | Fibromatosis, gingival, 1 | Enrichment | SOS1 | 1.36 |
| 520 | Otodental dysplasia | Enrichment | FGF3 | 1.36 |
| 521 | Costello syndrome | Enrichment | HRAS | 1.36 |
| 522 | Fanconi-bickel syndrome | Enrichment | SLC2A2 | 1.36 |
| 523 | Glycogen storage disease 0, liver | Enrichment | GYS2 | 1.36 |
| 524 | Epidermolysis bullosa, junctional 2c, laryngoonychocutaneous | Enrichment | LAMA3 | 1.36 |
| 525 | Bruck syndrome 1 | Enrichment | COL1A2 | 1.36 |
| 526 | Intracranial hypertension, idiopathic | Enrichment | FLT4 | 1.36 |
| 527 | Myasthenic syndrome, congenital, 5 | Enrichment | LAMB2 | 1.36 |
| 528 | Dystonia 9 | Enrichment | SLC2A1 | 1.36 |
| 529 | Pulmonary hypoplasia, primary | Enrichment | FGF10 | 1.36 |
| 530 | Immunodeficiency 33 | Enrichment | IKBKG | 1.36 |
| 531 | Pulmonic stenosis | Enrichment | SOS1 | 1.36 |
| 532 | Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 | Enrichment | PIK3R5 | 1.36 |
| 533 | Immunodeficiency 41 with lymphoproliferation and autoimmunity | Enrichment | IL2RA | 1.36 |
| 534 | Histiocytoma, angiomatoid fibrous | Enrichment | CREB1 | 1.36 |
| 535 | Piebald trait | Enrichment | KIT | 1.36 |
| 536 | Hyperinsulinemic hypoglycemia, familial, 4 | Enrichment | INSR | 1.36 |
| 537 | Aural atresia, congenital | Enrichment | FGFR2 | 1.36 |
| 538 | Glut1 deficiency syndrome 1 | Enrichment | SLC2A1 | 1.36 |
| 539 | Legg-calve-perthes disease | Enrichment | COL2A1 | 1.36 |
| 540 | Deafness, congenital, with inner ear agenesis, microtia, and microdontia | Enrichment | FGF3 | 1.36 |
| 541 | Leukocyte adhesion deficiency, type iii | Enrichment | ITGB2 | 1.36 |
| 542 | Lissencephaly 1 | Enrichment | LAMB1 | 1.36 |
| 543 | Neutrophilia, hereditary | Enrichment | CSF3R | 1.36 |
| 544 | Roifman-chitayat syndrome | Enrichment | PIK3CD | 1.36 |
| 545 | Specific language impairment 5 | Enrichment | COL4A4 | 1.36 |
| 546 | Immunodeficiency 45 | Enrichment | IFNAR2 | 1.36 |
| 547 | Growth hormone deficiency, isolated partial | Enrichment | GHR | 1.36 |
| 548 | Angioma, tufted | Enrichment | KDR | 1.36 |
| 549 | Maturity-onset diabetes of the young, type 10 | Enrichment | INS | 1.36 |
| 550 | Night blindness, congenital stationary, type 1h | Enrichment | GNB3 | 1.36 |
| 551 | Noonan syndrome 8 | Enrichment | PIK3CA | 1.36 |
| 552 | Pierson syndrome | Enrichment | LAMB2 | 1.36 |
| 553 | Thrombocythemia 3 | Enrichment | JAK2 | 1.36 |
| 554 | Neutropenia, severe congenital, 7, autosomal recessive | Enrichment | CSF3R | 1.36 |
| 555 | Multiple endocrine neoplasia, type iv | Enrichment | CDKN1B | 1.36 |
| 556 | Houge-janssens syndrome 1 | Enrichment | PPP2R5D | 1.36 |
| 557 | Antley-bixler syndrome without genital anomalies or disordered steroidogenesis | Enrichment | FGFR2 | 1.36 |
| 558 | Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy, 1 | Enrichment | COL4A2 | 1.36 |
| 559 | Combined osteogenesis imperfecta and ehlers-danlos syndrome 1 | Enrichment | COL1A1 | 1.36 |
| 560 | Epidermolysis bullosa, junctional 3b, severe | Enrichment | LAMC2 | 1.36 |
| 561 | Epidermolysis bullosa, junctional 3a, intermediate | Enrichment | LAMC2 | 1.36 |
| 562 | Waardenburg syndrome, type 2f | Enrichment | KITLG | 1.36 |
| 563 | Hyperproinsulinemia | Enrichment | INS | 1.36 |
| 564 | Fibromuscular dysplasia, multifocal | Enrichment | COL5A1 | 1.36 |
| 565 | Diamond-blackfan anemia-like | Enrichment | EPO | 1.36 |
| 566 | Epidermolysis bullosa, junctional 2a, intermediate | Enrichment | LAMA3 | 1.36 |
| 567 | Epidermolysis bullosa, junctional 5a, intermediate | Enrichment | ITGB4 | 1.36 |
| 568 | Myoectodermal gonadal dysgenesis syndrome | Enrichment | PPP2R3C | 1.36 |
| 569 | Spermatogenic failure 36 | Enrichment | PPP2R3C | 1.36 |
| 570 | Cebalid syndrome | Enrichment | MTOR | 1.36 |
| 571 | Polymicrogyria with or without vascular-type ehlers-danlos syndrome | Enrichment | COL3A1 | 1.36 |
| 572 | Infantile myofibromatosis | Enrichment | PDGFRB | 1.36 |
| 573 | Nephrotic syndrome, type 5, with or without ocular abnormalities | Enrichment | LAMB2 | 1.36 |
| 574 | Primary cutaneous amyloidosis | Enrichment | OSMR | 1.36 |
| 575 | Epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome | Enrichment | ITGA3 | 1.36 |
| 576 | Childhood hepatocellular carcinoma | Enrichment | MET | 1.36 |
| 577 | Glucose transporter type 1 deficiency syndrome | Enrichment | SLC2A1 | 1.36 |
| 578 | Polyhydramnios, megalencephaly, and symptomatic epilepsy | Enrichment | STRADA | 1.36 |
| 579 | Glycogen storage disease 0, muscle | Enrichment | GYS1 | 1.36 |
| 580 | Aortic dissection | Enrichment | COL3A1 | 1.36 |
| 581 | Senior-loken syndrome 7 | Enrichment | AKT3 | 1.36 |
| 582 | Split hand-foot malformation | Enrichment | FGFR2 | 1.36 |
| 583 | Erythrocytosis, familial, 3 | Enrichment | EPAS1 | 1.36 |
| 584 | Papillary renal cell carcinoma | Enrichment | MET | 1.36 |
| 585 | Glomerulonephritis | Enrichment | COL4A4 | 1.36 |
| 586 | Severe congenital neutropenia 7 | Enrichment | CSF3R | 1.36 |
| 587 | Immunodeficiency 104, severe combined | Enrichment | IL7R | 1.36 |
| 588 | Diabetes mellitus, permanent neonatal, 4 | Enrichment | INS | 1.36 |
| 589 | Autoinflammation, immune dysregulation, and eosinophilia | Enrichment | JAK1 | 1.36 |
| 590 | Ectodermal dysplasia and immune deficiency | Enrichment | IKBKG | 1.36 |
| 591 | Multiple sclerosis 3 | Enrichment | IL7R | 1.36 |
| 592 | Familial avascular necrosis of the femoral head | Enrichment | COL2A1 | 1.36 |
| 593 | Immune system disease | Enrichment | PIK3CD | 1.36 |
| 594 | Bardet-biedl syndrome 16 | Enrichment | AKT3 | 1.36 |
| 595 | Epidermolysis bullosa, junctional 2b, severe | Enrichment | LAMA3 | 1.36 |
| 596 | Smith-kingsmore syndrome | Enrichment | MTOR | 1.36 |
| 597 | Hereditary lymphedema i | Enrichment | FLT4 | 1.36 |
| 598 | Glucosephosphate dehydrogenase deficiency | Enrichment | IKBKG | 1.36 |
| 599 | Polycythemia | Enrichment | JAK2 | 1.36 |
| 600 | Lymphatic malformation 10 | Enrichment | ANGPT2 | 1.36 |
| 601 | Glycogen storage disorder due to hepatic glycogen synthase deficiency | Enrichment | GYS2 | 1.36 |
| 602 | Houge-janssens syndrome 3 | Enrichment | PPP2CA | 1.36 |
| 603 | Interfrontal craniofaciosynostosis | Enrichment | FGFR1 | 1.36 |
| 604 | Localized junctional epidermolysis bullosa, non-herlitz type | Enrichment | ITGB4 | 1.36 |
| 605 | Autosomal dominant nonsyndromic deafness | Enrichment | FGFR2 | 1.36 |
| 606 | Chronic eosinophilic leukemia | Enrichment | PDGFRA | 1.36 |
| 607 | Transient infantile hypertriglyceridemia and hepatosteatosis | Enrichment | CREB3L3 | 1.36 |
| 608 | Vacterl with hydrocephalus | Enrichment | PTEN | 1.36 |
| 609 | Growth delay due to insulin-like growth factor type 1 deficiency | Enrichment | IGF1 | 1.36 |
| 610 | Hypereosinophilic syndrome | Enrichment | JAK2 | 1.36 |
| 611 | Glycogen storage disease due to muscle and heart glycogen synthase deficiency | Enrichment | GYS1 | 1.36 |
| 612 | Dentinogenesis imperfecta | Enrichment | COL1A2 | 1.36 |
| 613 | B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality | Enrichment | PDGFRA | 1.36 |
| 614 | B-lymphoblastic leukemia/lymphoma with t | Enrichment | KIT | 1.36 |
| 615 | Juvenile polyposis of infancy | Enrichment | PTEN | 1.36 |
| 616 | Tafro syndrome | Enrichment | MAP2K2 | 1.36 |
| 617 | Oculootodental syndrome | Enrichment | FGF3 | 1.36 |
| 618 | Cerebral visual impairment | Enrichment | GNB1 | 1.36 |
| 619 | Wooly hair nevus | Enrichment | HRAS | 1.36 |
| 620 | Isolated macular dystrophy | Enrichment | COL4A5, ITGA4 | 1.33 |
| 621 | Microform holoprosencephaly | Enrichment | FGF8, FGFR1 | 1.32 |
| 622 | Lobar holoprosencephaly | Enrichment | FGF8, FGFR1 | 1.32 |
| 623 | Hereditary breast ovarian cancer syndrome | Enrichment | BRCA1, KRAS, PTEN, TP53 | 1.32 |
| 624 | Burkitt lymphoma | Enrichment | MYC | 1.31 |
| 625 | Adrenocortical carcinoma, hereditary | Enrichment | TP53 | 1.31 |
| 626 | Insensitivity to pain, congenital, with anhidrosis | Enrichment | NTRK1 | 1.31 |
| 627 | Trichomegaly | Enrichment | FGF5 | 1.31 |
| 628 | Phosphoenolpyruvate carboxykinase deficiency, mitochondrial | Enrichment | PCK2 | 1.31 |
| 629 | Neutropenia, severe congenital, 4, autosomal recessive | Enrichment | G6PC3 | 1.31 |
| 630 | Silver-russell syndrome 3 | Enrichment | IGF2 | 1.31 |
| 631 | Lymphoma, hodgkin, classic | Enrichment | TP53 | 1.31 |
| 632 | Immunodeficiency, common variable, 12, with autoimmunity | Enrichment | NFKB1 | 1.31 |
| 633 | Pain sensitivity quantitative trait locus 1 | Enrichment | NTRK1 | 1.31 |
| 634 | Stickler syndrome, type vi | Enrichment | COL9A3 | 1.31 |
| 635 | Intellectual developmental disorder, autosomal dominant 48 | Enrichment | RAC1 | 1.31 |
| 636 | Fanconi anemia, complementation group s | Enrichment | BRCA1 | 1.31 |
| 637 | Autoinflammatory disease, familial, behcet-like 3 | Enrichment | RELA | 1.31 |
| 638 | Kowarski syndrome | Enrichment | GH1 | 1.31 |
| 639 | Intravascular large b-cell lymphoma | Enrichment | BCL2 | 1.31 |
| 640 | Pancreatic cancer 4 | Enrichment | BRCA1 | 1.31 |
| 641 | Rela fusion-positive ependymoma | Enrichment | RELA | 1.31 |
| 642 | Acute basophilic leukemia | Enrichment | MYB | 1.31 |
| 643 | Congenital fibrosarcoma | Enrichment | TP53 | 1.31 |
| 644 | Li-fraumeni syndrome 1 | Enrichment | TP53 | 1.31 |
| 645 | Sarcoma | Enrichment | TP53 | 1.31 |
| 646 | Angiocentric glioma | Enrichment | MYB | 1.31 |
| 647 | Hodgkin's lymphoma | Enrichment | TP53 | 1.31 |
| 648 | Lodder-merla syndrome, type 1, with impaired intellectual development and cardiac arrhythmia | Enrichment | GNB5 | 1.31 |
| 649 | Inflammatory breast carcinoma | Enrichment | BRCA1 | 1.31 |
| 650 | Acute myeloid leukemia without maturation | Enrichment | FLT3 | 1.31 |
| 651 | Severe congenital neutropenia 4 | Enrichment | G6PC3 | 1.31 |
| 652 | Peritoneum cancer | Enrichment | BRCA1 | 1.31 |
| 653 | Bilateral breast cancer | Enrichment | BRCA1 | 1.31 |
| 654 | Short stature due to growth hormone qualitative anomaly | Enrichment | GH1 | 1.31 |
| 655 | Common variable immunodeficiency phenotype due to cd19/cd81 deficiency | Enrichment | CD19 | 1.31 |
| 656 | Mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2) | Enrichment | FLT3 | 1.31 |
| 657 | Common variable immunodeficiency 12 | Enrichment | NFKB1 | 1.31 |
| 658 | Silver-russell syndrome due to an imprinting defect of 11p15 | Enrichment | IGF2 | 1.31 |
| 659 | Pleomorphic rhabdomyosarcoma | Enrichment | TP53 | 1.31 |
| 660 | Silver-russell syndrome due to 11p15 microduplication | Enrichment | IGF2 | 1.31 |
| 661 | Alzheimer disease, familial, 1 | Enrichment | CSF1R, NOS3 | 1.27 |
| 662 | Hypertension, essential | Enrichment | GNB3, NOS3 | 1.27 |
| 663 | Cleft palate, isolated | Enrichment | COL11A1, GNB1 | 1.27 |
| 664 | Hypertension | Enrichment | COL4A4, COL4A5 | 1.23 |
| 665 | Semilobar holoprosencephaly | Enrichment | FGF8, FGFR1 | 1.22 |
| 666 | Benign epilepsy with centrotemporal spikes | Enrichment | RELN, SLC2A1, STRADA | 1.20 |
| 667 | Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-negative, nk cell-negative, due to adenosine deaminase deficiency | Enrichment | JAK3 | 1.18 |
| 668 | Hyper-ige syndrome 1, autosomal dominant, with recurrent infections | Enrichment | ITGB3 | 1.18 |
| 669 | Achondroplasia | Enrichment | FGFR3 | 1.18 |
| 670 | Mccune-albright syndrome | Enrichment | COL2A1 | 1.18 |
| 671 | Type 1 diabetes mellitus 2 | Enrichment | INS | 1.18 |
| 672 | Retinal arteries, tortuosity of | Enrichment | COL4A1 | 1.18 |
| 673 | Hypogonadotropic hypogonadism 2 with or without anosmia | Enrichment | FGFR1 | 1.18 |
| 674 | Larsen syndrome | Enrichment | FGFR3 | 1.18 |
| 675 | Spondyloepiphyseal dysplasia congenita | Enrichment | COL2A1 | 1.18 |
| 676 | Megalocornea | Enrichment | COL11A1 | 1.18 |
| 677 | Hypophosphatasia, infantile | Enrichment | COL11A2 | 1.18 |
| 678 | Polycythemia vera | Enrichment | JAK2 | 1.18 |
| 679 | Pompe disease, infantile-onset | Enrichment | PIK3CA | 1.18 |
| 680 | Periventricular nodular heterotopia 1 | Enrichment | VWF | 1.18 |
| 681 | Leukoencephalopathy, hereditary diffuse, with spheroids 1 | Enrichment | CSF1R | 1.18 |
| 682 | Ifap syndrome 1, with or without bresheck syndrome | Enrichment | SREBF1 | 1.18 |
| 683 | Polycystic kidney disease, infantile severe, with tuberous sclerosis | Enrichment | TSC2 | 1.18 |
| 684 | Severe combined immunodeficiency, x-linked | Enrichment | IL2RG | 1.18 |
| 685 | Glomerulopathy with fibronectin deposits 2 | Enrichment | FN1 | 1.18 |
| 686 | Nuchal bleb, familial | Enrichment | SOS1 | 1.18 |
| 687 | Ehlers-danlos syndrome, classic-like, 1 | Enrichment | TNXB | 1.18 |
| 688 | Combined immunodeficiency, x-linked | Enrichment | IL2RG | 1.18 |
| 689 | Glut1 deficiency syndrome 2 | Enrichment | SLC2A1 | 1.18 |
| 690 | Muscular dystrophy, congenital merosin-deficient, 1a | Enrichment | LAMA2 | 1.18 |
| 691 | Caffey disease | Enrichment | COL1A1 | 1.18 |
| 692 | Muscular dystrophy, congenital, due to integrin alpha-7 deficiency | Enrichment | ITGA7 | 1.18 |
| 693 | Tuberous sclerosis 2 | Enrichment | TSC2 | 1.18 |
| 694 | Brain small vessel disease 2 | Enrichment | COL4A2 | 1.18 |
| 695 | Lipodystrophy, familial partial, type 6 | Enrichment | LIPE | 1.18 |
| 696 | Chromosome 8p11 myeloproliferative syndrome | Enrichment | FGFR1 | 1.18 |
| 697 | Woolly hair, autosomal recessive 3 | Enrichment | LPAR6 | 1.18 |
| 698 | Epilepsy, familial temporal lobe, 7 | Enrichment | RELN | 1.18 |
| 699 | Neonatal nephrocutaneous inflammatory syndrome | Enrichment | EGFR | 1.18 |
| 700 | Microangiopathy and leukoencephalopathy, pontine, autosomal dominant | Enrichment | COL4A1 | 1.18 |
| 701 | Vesicoureteral reflux 8 | Enrichment | TNXB | 1.18 |
| 702 | Epidermolysis bullosa, junctional 6, with pyloric atresia | Enrichment | ITGA6 | 1.18 |
| 703 | Hypotrichosis 8 | Enrichment | LPAR6 | 1.18 |
| 704 | Ehlers-danlos syndrome, classic-like, 3 | Enrichment | THBS2 | 1.18 |
| 705 | Primary polycythemia | Enrichment | EPOR | 1.18 |
| 706 | Poretti-boltshauser syndrome | Enrichment | LAMA1 | 1.18 |
| 707 | Chromosome 17q23.1-q23.2 deletion syndrome | Enrichment | SLC2A1 | 1.18 |
| 708 | Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps | Enrichment | COL4A1 | 1.18 |
| 709 | Xanthinuria, type ii | Enrichment | TSC2 | 1.18 |
| 710 | Kyphosis | Enrichment | RELN | 1.18 |
| 711 | Familial vesicoureteral reflux | Enrichment | TNXB | 1.18 |
| 712 | Immunodeficiency 44 | Enrichment | IFNAR2 | 1.18 |
| 713 | Laryngeal squamous cell carcinoma | Enrichment | PTEN | 1.18 |
| 714 | Growth delay due to insulin-like growth factor i resistance | Enrichment | IGF1R | 1.18 |
| 715 | Bleeding disorder, platelet-type, 24 | Enrichment | ITGB3 | 1.18 |
| 716 | Neonatal inflammatory skin and bowel disease | Enrichment | EGFR | 1.18 |
| 717 | Melanoma of soft tissue | Enrichment | CREB1 | 1.18 |
| 718 | Alopecia - intellectual disability syndrome | Enrichment | ITGB6 | 1.18 |
| 719 | Renal cell carcinoma | Enrichment | MET | 1.18 |
| 720 | Enchondromatosis | Enrichment | HIF1A | 1.18 |
| 721 | Keratoacanthoma | Enrichment | PIK3CA | 1.18 |
| 722 | Apc-associated polyposis conditions | Enrichment | STK11 | 1.18 |
| 723 | Epilepsy with auditory features | Enrichment | RELN | 1.18 |
| 724 | Lama2-related muscular dystrophy | Enrichment | LAMA2 | 1.18 |
| 725 | Diffuse large b-cell lymphoma | Enrichment | FOXO1, PTEN | 1.18 |
| 726 | Melanoma, cutaneous malignant 1 | Enrichment | CDK4, STK11 | 1.18 |
| 727 | Centralopathic epilepsy | Enrichment | RELN, SLC2A1, STRADA | 1.15 |
| 728 | Craniosynostosis | Enrichment | FGFR2, FGFR3 | 1.14 |
| 729 | Thyroid carcinoma, familial medullary | Enrichment | NTRK1 | 1.14 |
| 730 | Tumoral calcinosis, hyperphosphatemic, familial, 1 | Enrichment | FGF23 | 1.14 |
| 731 | Hypophosphatemic rickets, autosomal dominant | Enrichment | FGF23 | 1.14 |
| 732 | Immunodeficiency 98 with autoinflammation, x-linked | Enrichment | FASLG | 1.14 |
| 733 | Osteogenic sarcoma | Enrichment | TP53 | 1.14 |
| 734 | Nasopharyngeal carcinoma | Enrichment | TP53 | 1.14 |
| 735 | Pilarowski-bjornsson syndrome | Enrichment | COL4A3 | 1.14 |
| 736 | Alport syndrome 3b, autosomal recessive | Enrichment | COL4A3 | 1.14 |
| 737 | Isolated growth hormone deficiency, type ib | Enrichment | GH1 | 1.14 |
| 738 | Atypical teratoid rhabdoid tumor | Enrichment | TP53 | 1.14 |
| 739 | Anaplastic astrocytoma | Enrichment | TP53 | 1.14 |
| 740 | Squamous cell carcinoma | Enrichment | TP53 | 1.14 |
| 741 | Adenocarcinoma | Enrichment | TP53 | 1.14 |
| 742 | Hematuria, benign familial, 2 | Enrichment | COL4A3 | 1.14 |
| 743 | Bone osteosarcoma | Enrichment | TP53 | 1.14 |
| 744 | Adenoid cystic carcinoma | Enrichment | MYB | 1.14 |
| 745 | Mixed phenotype acute leukemia with t | Enrichment | FLT3 | 1.14 |
| 746 | Beckwith-wiedemann syndrome due to imprinting defect of 11p15 | Enrichment | IGF2 | 1.14 |
| 747 | Beckwith-wiedemann syndrome | Enrichment | COL6A1, IGF2 | 1.14 |
| 748 | Myopathy | Enrichment | COL6A1, COL6A2, COL6A3 | 1.11 |
| 749 | Amelogenesis imperfecta, type iiia | Enrichment | ITGB6 | 1.06 |
| 750 | Hypertriglyceridemia 1 | Enrichment | CREB3L3 | 1.06 |
| 751 | Diffuse gastric and lobular breast cancer syndrome | Enrichment | KRAS | 1.06 |
| 752 | Huntington disease | Enrichment | SLC2A3 | 1.06 |
| 753 | Phenylketonuria | Enrichment | COL1A1 | 1.06 |
| 754 | Schizencephaly | Enrichment | COL4A1 | 1.06 |
| 755 | Spastic paraplegia 17, autosomal dominant | Enrichment | GNG3 | 1.06 |
| 756 | Budd-chiari syndrome | Enrichment | JAK2 | 1.06 |
| 757 | Neurofibromatosis-noonan syndrome | Enrichment | MAP2K2 | 1.06 |
| 758 | Lipodystrophy, congenital generalized, type 2 | Enrichment | GNG3 | 1.06 |
| 759 | Glaucoma 3, primary infantile, b | Enrichment | TEK | 1.06 |
| 760 | Chromosome 22q11.2 deletion syndrome, distal | Enrichment | MAPK1 | 1.06 |
| 761 | Epidermolysis bullosa simplex 5c, with pyloric atresia | Enrichment | ITGB4 | 1.06 |
| 762 | Retinitis pigmentosa 26 | Enrichment | ITGA4 | 1.06 |
| 763 | Multiple synostoses syndrome | Enrichment | FGF9 | 1.06 |
| 764 | Neonatal diabetes mellitus | Enrichment | INS | 1.06 |
| 765 | Hepatitis b | Enrichment | IFNAR2 | 1.06 |
| 766 | Cerebrovascular disease | Enrichment | PIK3CA | 1.06 |
| 767 | Noonan syndrome with multiple lentigines | Enrichment | RAF1 | 1.06 |
| 768 | Pilocytic astrocytoma | Enrichment | KRAS | 1.06 |
| 769 | Epidermolytic nevus | Enrichment | HRAS | 1.06 |
| 770 | Idiopathic achalasia | Enrichment | NOS1 | 1.06 |
| 771 | Familial cerebral cavernous malformations | Enrichment | PIK3CA | 1.06 |
| 772 | Adenosine deaminase deficiency | Enrichment | JAK3 | 1.06 |
| 773 | Non-syndromic bicoronal craniosynostosis | Enrichment | FGFR3 | 1.06 |
| 774 | Pediatric systemic lupus erythematosus | Enrichment | SPP1 | 1.06 |
| 775 | Primary hyperparathyroidism | Enrichment | CDKN1B | 1.06 |
| 776 | Systemic mastocytosis with associated hematologic neoplasm | Enrichment | KIT | 1.06 |
| 777 | Rare x-linked non-syndromic sensorineural deafness type dfn | Enrichment | COL4A6 | 1.06 |
| 778 | Gingival fibromatosis | Enrichment | SOS1 | 1.06 |
| 779 | Hereditary angioedema with normal c1inh not related to f12 or plg variant | Enrichment | ANGPT1 | 1.06 |
| 780 | Familial sick sinus syndrome | Enrichment | GNB2 | 1.06 |
| 781 | Focal segmental glomerulosclerosis | Enrichment | COL4A4, COL4A5 | 1.06 |
| 782 | Thrombocytopenia | Enrichment | ITGA2B, ITGB3, VWF | 1.04 |
| 783 | Malaria | Enrichment | IKBKG, NOS2 | 1.04 |
| 784 | Hepatoblastoma | Enrichment | FGFR3, TP53 | 1.02 |
| 785 | Kaposi sarcoma | Enrichment | IL6 | 1.02 |
| 786 | Isolated growth hormone deficiency, type ii | Enrichment | GH1 | 1.02 |
| 787 | Small cell cancer of the lung | Enrichment | TP53 | 1.02 |
| 788 | Glycogen storage disease ia | Enrichment | G6PC1 | 1.02 |
| 789 | Thyroid cancer, nonmedullary, 1 | Enrichment | TP53 | 1.02 |
| 790 | Polyposis syndrome, hereditary mixed, 1 | Enrichment | BRCA1 | 1.02 |
| 791 | Autoimmune lymphoproliferative syndrome | Enrichment | FASLG | 1.02 |
| 792 | Cholangiocarcinoma | Enrichment | BRCA1 | 1.02 |
| 793 | Mantle cell lymphoma | Enrichment | CCND1 | 1.02 |
| 794 | Chronic myelomonocytic leukemia | Enrichment | FLT3 | 1.02 |
| 795 | Embryonal rhabdomyosarcoma | Enrichment | TP53 | 1.02 |
| 796 | Silver-russell syndrome due to a point mutation | Enrichment | IGF2 | 1.02 |
| 797 | Inherited epidermodysplasia verruciformis | Enrichment | IL7 | 1.02 |
| 798 | Systemic-onset juvenile idiopathic arthritis | Enrichment | IL6 | 1.02 |
| 799 | Male infertility due to gonadal dysgenesis or sperm disorder | Enrichment | SOS2 | 1.02 |
| 800 | Scoliosis | Enrichment | COL2A1, RELN | 1.00 |
| 801 | Tooth agenesis | Enrichment | FGFR1, TGFA | 0.98 |
| 802 | Cataract 6, multiple types | Enrichment | EPHA2 | 0.97 |
| 803 | Capillary malformations, congenital | Enrichment | PIK3CA | 0.97 |
| 804 | Enchondromatosis, multiple, ollier type | Enrichment | HIF1A | 0.97 |
| 805 | Alzheimer disease 2 | Enrichment | NOS3 | 0.97 |
| 806 | Epidermolysis bullosa simplex 1c, localized | Enrichment | ITGB4 | 0.97 |
| 807 | Microcephaly 1, primary, autosomal recessive | Enrichment | ANGPT2 | 0.97 |
| 808 | Anemia, congenital, nonspherocytic hemolytic, 1 | Enrichment | IKBKG | 0.97 |
| 809 | Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative | Enrichment | JAK3 | 0.97 |
| 810 | Rhabdomyosarcoma 2 | Enrichment | FOXO1 | 0.97 |
| 811 | Macrocephaly/autism syndrome | Enrichment | PTEN | 0.97 |
| 812 | Familial adenomatous polyposis 1 | Enrichment | STK11 | 0.97 |
| 813 | Lissencephaly 2 | Enrichment | RELN | 0.97 |
| 814 | Glanzmann thrombasthenia 2 | Enrichment | ITGB3 | 0.97 |
| 815 | Muscular dystrophy, limb-girdle, autosomal recessive 23 | Enrichment | LAMA2 | 0.97 |
| 816 | Familial woolly hair syndrome | Enrichment | LPAR6 | 0.97 |
| 817 | Myeloproliferative neoplasm | Enrichment | JAK2 | 0.97 |
| 818 | Hemangioma | Enrichment | PTEN | 0.97 |
| 819 | Aplasia cutis congenita | Enrichment | ITGB4 | 0.97 |
| 820 | Aniridia | Enrichment | EPHA2 | 0.97 |
| 821 | Generalized juvenile polyposis/juvenile polyposis coli | Enrichment | STK11 | 0.97 |
| 822 | Familial cerebral saccular aneurysm | Enrichment | COL3A1 | 0.97 |
| 823 | Tetralogy of fallot | Enrichment | FLT4, KDR | 0.95 |
| 824 | Hydrops fetalis, nonimmune | Enrichment | FLT4, HRAS | 0.95 |
| 825 | Von hippel-lindau syndrome | Enrichment | CCND1 | 0.92 |
| 826 | Rheumatoid arthritis, systemic juvenile | Enrichment | IL6 | 0.92 |
| 827 | Breast-ovarian cancer, familial 2 | Enrichment | BRCA1 | 0.92 |
| 828 | Follicular lymphoma | Enrichment | BCL2 | 0.92 |
| 829 | Lymphoma | Enrichment | TP53 | 0.92 |
| 830 | Hypoglycemia | Enrichment | G6PC1 | 0.92 |
| 831 | Strabismus | Enrichment | GNB1, SLC2A1 | 0.92 |
| 832 | Developmental dysplasia of the hip 1 | Enrichment | COL2A1 | 0.90 |
| 833 | Klippel-trenaunay-weber syndrome | Enrichment | PIK3CA | 0.90 |
| 834 | Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency | Enrichment | TNXB | 0.90 |
| 835 | Split-hand/foot malformation 1 | Enrichment | FGFR2 | 0.90 |
| 836 | Anterior segment dysgenesis 5 | Enrichment | COL4A1 | 0.90 |
| 837 | Inguinal hernia | Enrichment | COL5A1 | 0.90 |
| 838 | Pain disorder | Enrichment | COL5A1 | 0.90 |
| 839 | Sporadic pheochromocytoma/secreting paraganglioma | Enrichment | EPAS1 | 0.90 |
| 840 | 21-hydroxylase-deficient congenital adrenal hyperplasia | Enrichment | TNXB | 0.90 |
| 841 | Severe covid-19 | Enrichment | ITGAV, JAK3 | 0.87 |
| 842 | Microcephaly | Enrichment | COL4A1, GNB1, IGF1R, MAPK1, SLC2A1 | 0.85 |
| 843 | Wilms tumor, aniridia, genitourinary anomalies, and impaired intellectual development syndrome | Enrichment | BDNF | 0.85 |
| 844 | Adrenocortical carcinoma | Enrichment | TP53 | 0.85 |
| 845 | Polycystic kidney disease 1 with or without polycystic liver disease | Enrichment | TSC2 | 0.84 |
| 846 | Glaucoma 3, primary congenital, a | Enrichment | TEK | 0.84 |
| 847 | Myelofibrosis | Enrichment | JAK2 | 0.84 |
| 848 | Waardenburg syndrome, type 2e | Enrichment | KITLG | 0.84 |
| 849 | Polycystic kidney disease 1 | Enrichment | TSC2 | 0.84 |
| 850 | Megacolon | Enrichment | AKT3 | 0.84 |
| 851 | Epidermolysis bullosa simplex | Enrichment | ITGB4 | 0.84 |
| 852 | Paroxysmal dystonia | Enrichment | SLC2A1 | 0.84 |
| 853 | Esophageal cancer | Enrichment | TP53 | 0.79 |
| 854 | Silver-russell syndrome 1 | Enrichment | IGF2 | 0.79 |
| 855 | Common variable immunodeficiency | Enrichment | NFKB1 | 0.79 |
| 856 | Hypophosphatemic rickets | Enrichment | FGF23 | 0.79 |
| 857 | Arthrogryposis, distal, type 1a | Enrichment | MET | 0.78 |
| 858 | Gastroesophageal reflux | Enrichment | COL5A1 | 0.78 |
| 859 | Spastic paraplegia 4, autosomal dominant | Enrichment | COL3A1 | 0.78 |
| 860 | Renal hypodysplasia/aplasia 1 | Enrichment | ITGA8 | 0.78 |
| 861 | Orthostatic intolerance | Enrichment | COL5A1 | 0.78 |
| 862 | Severe congenital neutropenia | Enrichment | CSF3R | 0.78 |
| 863 | Alternating hemiplegia of childhood | Enrichment | SLC2A1 | 0.78 |
| 864 | Congenital muscular dystrophy | Enrichment | LAMA2 | 0.78 |
| 865 | Hypothyroidism | Enrichment | GNB1 | 0.78 |
| 866 | Permanent neonatal diabetes mellitus | Enrichment | INS | 0.78 |
| 867 | Early-onset posterior polar cataract | Enrichment | EPHA2 | 0.78 |
| 868 | Glioma susceptibility 1 | Enrichment | TP53 | 0.74 |
| 869 | Isolated growth hormone deficiency, type ia | Enrichment | GH1 | 0.74 |
| 870 | Lymphoma, non-hodgkin, familial | Enrichment | TP53 | 0.74 |
| 871 | Orofacial cleft 1 | Enrichment | FGF10 | 0.74 |
| 872 | Coronary heart disease 5 | Enrichment | IKBKG | 0.74 |
| 873 | Leukemia, acute lymphoblastic 3 | Enrichment | JAK2 | 0.74 |
| 874 | Myoclonic-atonic epilepsy | Enrichment | SLC2A1 | 0.74 |
| 875 | Hypogonadotropic hypogonadism | Enrichment | FGFR1 | 0.74 |
| 876 | Ventricular septal defect | Enrichment | TEK | 0.74 |
| 877 | Hypotrichosis simplex | Enrichment | LPAR6 | 0.74 |
| 878 | Familial thoracic aortic aneurysm and dissection | Enrichment | COL3A1 | 0.74 |
| 879 | Primary autosomal recessive microcephaly | Enrichment | ANGPT2, CDK6 | 0.72 |
| 880 | Marfan syndrome | Enrichment | COL2A1 | 0.70 |
| 881 | Meier-gorlin syndrome 1 | Enrichment | FGFR2 | 0.70 |
| 882 | Peters-plus syndrome | Enrichment | COL4A1 | 0.70 |
| 883 | Stroke, ischemic | Enrichment | NOS3 | 0.70 |
| 884 | Polymicrogyria | Enrichment | AKT3 | 0.70 |
| 885 | Inflammatory bowel disease 1 | Enrichment | IL6 | 0.69 |
| 886 | Neurodevelopmental disorder with dysmorphic facies and distal limb anomalies | Enrichment | RAC1 | 0.69 |
| 887 | Congenital central hypoventilation syndrome | Enrichment | BDNF | 0.69 |
| 888 | Primary hyperaldosteronism | Enrichment | TP53 | 0.69 |
| 889 | Genetic steroid-resistant nephrotic syndrome | Enrichment | COL4A3, LAMA5 | 0.68 |
| 890 | Frontotemporal dementia 1 | Enrichment | CSF1R | 0.66 |
| 891 | Combined immunodeficiency | Enrichment | IL2RG | 0.66 |
| 892 | Ichthyosis | Enrichment | IL2RB | 0.66 |
| 893 | Combined t cell and b cell immunodeficiency | Enrichment | IL2RG | 0.66 |
| 894 | Diabetes mellitus | Enrichment | INS | 0.66 |
| 895 | Combined t and b cell immunodeficiency | Enrichment | IL2RG | 0.66 |
| 896 | Presynaptic congenital myasthenic syndromes | Enrichment | LAMA5 | 0.66 |
| 897 | Ciliary dyskinesia, primary, 3 | Enrichment | NFKB1 | 0.65 |
| 898 | Familial colorectal cancer | Enrichment | TP53 | 0.65 |
| 899 | Autism spectrum disorder | Enrichment | GNB1, MAP2K1, PTEN, TSC2 | 0.65 |
| 900 | Septooptic dysplasia | Enrichment | FGFR1 | 0.63 |
| 901 | Renal hypodysplasia/aplasia 3 | Enrichment | FGFR3 | 0.63 |
| 902 | Cutis laxa | Enrichment | COL5A1 | 0.63 |
| 903 | Congenital long qt syndrome | Enrichment | SLC2A2 | 0.63 |
| 904 | Immune deficiency disease | Enrichment | SYK | 0.61 |
| 905 | Aortic valve disease 1 | Enrichment | SOS1 | 0.60 |
| 906 | Hypercholesterolemia, familial, 1 | Enrichment | GHR | 0.60 |
| 907 | Clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly | Enrichment | COL5A1 | 0.60 |
| 908 | Neural tube defects | Enrichment | ITGB1 | 0.60 |
| 909 | Alzheimer's disease | Enrichment | CSF1R | 0.60 |
| 910 | Clubfoot | Enrichment | COL5A1 | 0.60 |
| 911 | Amelogenesis imperfecta | Enrichment | LAMB3 | 0.60 |
| 912 | Protein-deficiency anemia | Enrichment | NRAS | 0.60 |
| 913 | West syndrome | Enrichment | SLC2A1, TSC2 | 0.59 |
| 914 | Hypogonadotropic hypogonadism 7 with or without anosmia | Enrichment | FGFR1 | 0.57 |
| 915 | Lipoid congenital adrenal hyperplasia | Enrichment | TNXB | 0.57 |
| 916 | Aortic aneurysm, familial thoracic 1 | Enrichment | COL3A1 | 0.57 |
| 917 | Walker-warburg syndrome | Enrichment | COL4A1 | 0.57 |
| 918 | Generalized epilepsy with febrile seizures plus | Enrichment | FGF13 | 0.57 |
| 919 | Cleft lip/palate | Enrichment | PDGFRA | 0.57 |
| 920 | 46,xy partial gonadal dysgenesis | Enrichment | SOS1 | 0.57 |
| 921 | Congenital nervous system abnormality | Enrichment | FGFR3, GNB5, PTEN, TSC2 | 0.56 |
| 922 | Nervous system disease | Enrichment | FGFR3, GNB5, PTEN, TSC2 | 0.56 |
| 923 | Breast-ovarian cancer, familial 1 | Enrichment | BRCA1 | 0.55 |
| 924 | Congenital myopathy 4a, autosomal dominant | Enrichment | ITGA7 | 0.54 |
| 925 | Corpus callosum, agenesis of | Enrichment | COL4A1 | 0.54 |
| 926 | Anterior segment dysgenesis | Enrichment | COL4A1 | 0.54 |
| 927 | Familial hypercholesterolemia | Enrichment | GHR | 0.54 |
| 928 | Autosomal dominant polycystic kidney disease | Enrichment | TSC2 | 0.54 |
| 929 | Isolated corpus callosum agenesis | Enrichment | COL4A1 | 0.54 |
| 930 | Rare genetic intellectual disability | Enrichment | MTOR | 0.54 |
| 931 | Septopreoptic holoprosencephaly | Enrichment | FGF8 | 0.54 |
| 932 | Intellectual disability-hypoplastic corpus callosum-preauricular tag syndrome | Enrichment | COL4A1 | 0.54 |
| 933 | Midline interhemispheric variant of holoprosencephaly | Enrichment | FGF8 | 0.54 |
| 934 | Sensorineural hearing loss | Enrichment | COL11A2, HGF | 0.54 |
| 935 | Periventricular nodular heterotopia | Enrichment | BRCA1 | 0.53 |
| 936 | Creatine phosphokinase, elevated serum | Enrichment | LAMA2 | 0.52 |
| 937 | Isolated elevated serum creatine phosphokinase levels | Enrichment | LAMA2 | 0.52 |
| 938 | Wilms tumor 1 | Enrichment | IGF2 | 0.50 |
| 939 | Atypical hemolytic-uremic syndrome | Enrichment | COL4A5 | 0.50 |
| 940 | Dandy-walker syndrome | Enrichment | PDGFRB | 0.50 |
| 941 | Cataract 44 | Enrichment | EPHA2 | 0.50 |
| 942 | Alobar holoprosencephaly | Enrichment | FGF8 | 0.50 |
| 943 | Rare autosomal recessive non-syndromic sensorineural deafness type dfnb | Enrichment | COL11A2, HGF, MET | 0.50 |
| 944 | Familial isolated dilated cardiomyopathy | Enrichment | LAMA4, RAF1 | 0.48 |
| 945 | Polycystic kidney disease | Enrichment | COL4A4 | 0.48 |
| 946 | Early-onset nuclear cataract | Enrichment | EPHA2 | 0.48 |
| 947 | Maturity-onset diabetes of the young | Enrichment | INS | 0.44 |
| 948 | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Enrichment | CSF1R, PPARGC1A | 0.43 |
| 949 | Lissencephaly | Enrichment | RELN | 0.42 |
| 950 | Behcet syndrome | Enrichment | TLR4 | 0.42 |
| 951 | Myocardial infarction | Enrichment | ITGB3 | 0.41 |
| 952 | Congenital stationary night blindness | Enrichment | GNB3 | 0.39 |
| 953 | Undetermined early-onset epileptic encephalopathy | Enrichment | FGF12, NTRK2 | 0.39 |
| 954 | Ear malformation | Enrichment | COL11A2 | 0.38 |
| 955 | Cardiomyopathy, familial hypertrophic, 1 | Enrichment | RAF1 | 0.38 |
| 956 | Muscular dystrophy | Enrichment | COL6A2 | 0.38 |
| 957 | Attention deficit-hyperactivity disorder | Enrichment | GNB5 | 0.37 |
| 958 | Developmental and epileptic encephalopathy 1 | Enrichment | SLC2A1 | 0.37 |
| 959 | Diamond-blackfan anemia 1 | Enrichment | TP53 | 0.36 |
| 960 | Hirschsprung disease 1 | Enrichment | SREBF1 | 0.32 |
| 961 | Long qt syndrome 1 | Enrichment | SLC2A2 | 0.31 |
| 962 | Stargardt disease 1 | Enrichment | COL2A1 | 0.31 |
| 963 | Peripheral nervous system disease | Enrichment | NGF | 0.29 |
| 964 | Neuropathy | Enrichment | NGF | 0.29 |
| 965 | Familial hypertrophic cardiomyopathy | Enrichment | RAF1 | 0.28 |
| 966 | Dilated cardiomyopathy | Enrichment | LAMA2, RAF1 | 0.27 |
| 967 | Cakut | Enrichment | COL4A1 | 0.27 |
| 968 | Left ventricular noncompaction | Enrichment | RAF1 | 0.26 |
| 969 | Dystonia | Enrichment | GNB1 | 0.26 |
| 970 | Systemic lupus erythematosus | Enrichment | SPP1 | 0.23 |
| 971 | Fanconi anemia, complementation group a | Enrichment | BRCA1 | 0.23 |
| 972 | Epilepsy | Enrichment | SLC2A1 | 0.23 |
| 973 | Diamond-blackfan anemia | Enrichment | TP53 | 0.22 |
| 974 | Charcot-marie-tooth disease | Enrichment | LAMA2 | 0.22 |
| 975 | Nonsyndromic hearing loss | Enrichment | COL11A2 | 0.21 |
| 976 | Autosomal dominant non-syndromic intellectual disability | Enrichment | GNB1 | 0.17 |
| 977 | Male infertility with azoospermia or oligozoospermia due to single gene mutation | Enrichment | FGF8 | 0.14 |
| 978 | Body mass index quantitative trait locus 11 | Enrichment | BDNF | 0.14 |
| 979 | Schizophrenia | Enrichment | RELN | 0.13 |
| 980 | Complex neurodevelopmental disorder | Enrichment | GNB2, PPP2CA | 0.12 |
| 981 | Cone-rod dystrophy 2 | Enrichment | ITGA4 | 0.11 |
| 982 | Autism | Enrichment | COL11A1 | 0.10 |
| 983 | Rare genetic deafness | Enrichment | COL11A2 | 0.08 |
| 984 | Hereditary retinal dystrophy | Enrichment | COL11A2, COL2A1, ITGA4, LAMA1 | 0.05 |
| 985 | Fundus dystrophy | Enrichment | COL11A2, COL2A1, ITGA4, LAMA1 | 0.05 |